Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy

Not Applicable

Withdrawn

Brief Summary: The purpose of this study is to see if PET/CT scans that use a radioactive substance called \[18F\] fluorothymidine (FLT), can detect and monitor changes in the tumor. Radioactive substances are used with PET/CT scans to "see" cancer cells, and are also called radiotracers. FLT is a new radiotracer that has been given to people in prior studies. FLT PET/CT is an experimental scan unlike FDG (fluorodeoxyglucose) PET scan which is a standard clinical scan and is commonly used. The investigators would like to know if there is any evidence of early treatment response by obtaining FLTPET/ CT scans before and after treatment.

Detailed Description: This protocol is an "umbrella" or "companion" protocol to be used in conjunction with other protocols that are evaluating treatment response in solid or hematologic malignancies. The aim of this protocol is to determine if PET imaging with the proliferation marker 18FFLT can monitor changes in FLT uptake parameters, in particular changes in the standardized uptake value (SUV), within tumor target lesions.

Recruitment & Eligibility

Inclusion Criteria

Patients with histologically-confirmed (confirmation done at MSKCC) malignancies.
Patients who have consented to a therapeutic protocol for the treatment of their cancer.
Patients must be ≥ 18 years old.

Exclusion Criteria

Patients who cannot undergo PET/CT scanning (i.e. because of weight limits, claustrophobia).
Women who are pregnant or breast-feeding.

Arm && Interventions

Group	Intervention	Description
Serial FLT PET Imaging	PET/CT scans	Patients will receive a target injection of up to 10 mCi of FLT. Optionally, dynamic PET imaging over a chosen index lesion (based on size and/or high FDG-avidity on preceding CT and/or FDG PET/CT scans done for clinical purpose such as staging), may be performed. Otherwise, static PET images are obtained at approximately 60 min (+15 min) post FLT injection. In general this "body" scan will cover at least the region from skull base to the upper thigh for extracranial malignancies; depending on the specific location, extremities maybe also be scanned (e.g., extremity sarcoma), or the scan may be restricted to the brain (e.g. glioma).
Serial FLT PET Imaging	[18F] FLT	Patients will receive a target injection of up to 10 mCi of FLT. Optionally, dynamic PET imaging over a chosen index lesion (based on size and/or high FDG-avidity on preceding CT and/or FDG PET/CT scans done for clinical purpose such as staging), may be performed. Otherwise, static PET images are obtained at approximately 60 min (+15 min) post FLT injection. In general this "body" scan will cover at least the region from skull base to the upper thigh for extracranial malignancies; depending on the specific location, extremities maybe also be scanned (e.g., extremity sarcoma), or the scan may be restricted to the brain (e.g. glioma).

Primary Outcome Measures

Name	Time	Method
change from pre- to posttreatment	4 years	We will describe the distribution of the change and explore if it is associated with the findings of standard-of-care imaging such as FDG-PET or CT/MRI using rank based methods such as Spearman correlation and the signed-ranks test. In addition we will also explore the value of the change in the FLT metrics in predicting the clinical outcome using logistic regression (for response) and proportional hazards regression (for progression and survival).

Secondary Outcome Measures

Name	Time	Method

Locations (1): Memorial Sloan Kettering Cancer Center
🇺🇸
New York, New York, United States

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial